Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Salix Pharmaceuticals, a company that develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases, has filed an efficacy supplement to NDA 21-361 for Xifaxan (rifaximin) 550mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome (Non-C IBS) and IBS-related bloating.
Subscribe to our email newsletter
By regulation, the FDA has 60 days to conduct a filing review to determine if the application is sufficiently complete to permit a substantive review.
Salix has requested Priority Review for this application. By regulation, the FDA should determine the review classification for this application within the 60-day period referenced above.
Xifaxan 550mg is indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients = 18 years of age. In the trials of Xifaxan for HE, 91% of the patients were using lactulose concomitantly.
Rifaximin is a gut-selective antibiotic with negligible systemic absorption and broad-spectrum activity in vitro against both gram-positive and gram-negative pathogens. Rifaximin has a similar tolerability profile to that of placebo.
Rifaximin tablets 200mg, which Salix markets in the US under the trade name Xifaxan (rifaximin) tablets 200mg, currently is approved for the treatment of patients, 12 years of age or older, with travelers’ diarrhea (TD) caused by non–invasive strains of Escherichia coli.
Rifaximin is approved in over 30 countries worldwide. Salix acquired rights to market rifaximin in North America from Alfa Wassermann SpA in Bologna, Italy. Alfa Wassermann has marketed Rifaximin in Italy under the trade name Normix for over 20 years.